Seeking Alpha

Mike Zaman's  Instablog

Mike Zaman
Send Message
View Mike Zaman's Instablogs on:
  • GW Pharmaceuticals Plc (GWPH) Cannabinoid Pipeline Expectations, GameStop Corp (GME) Profit Exceeds Guidance

    http://static.cdn-seekingalpha.com/uploads/2014/6/6/saupload_gwph.jpg GW Pharmaceuticals plc (NASDAQ:GWPH)

    A seizure is a temporary disturbance in brain function in which groups of nerve cells in the brain signal abnormally and excessively. Changes in the brain's electrical activity can cause dramatic, noticeable symptoms or even no symptoms at all. The symptoms of a severe seizure are often widely recognized, including violent shaking and loss of control. Usually, a seizure lasts from a few seconds to a few minutes.

    Epilepsy is a neurological condition which affects the nervous system. Epilepsy, also known as a seizure disorder, is characterized by a tendency to have recurrent seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but most of the time the cause is unknown

    Epilepsy affects not only the individual with epilepsy but also can have a great impact on all members of the family unit. People with epilepsy do not live in isolation. Many of the negative events experienced by children with epilepsy are likely to extend to all family members. As stress in the family increases, it may exasperate any pre-existing marital quarrels .

    Epilepsy is not a disease, mental illness or a sign of low intelligence. It is not contagious.

    Epilepsy is usually diagnosed in childhood and in people over the age of 65, but it can affect any one. According to the Centers for Disease Control and Prevention, epilepsy affects 65 million people worldwide.

    Dravet syndrome, also called severe myoclonic epilepsy of infancy, is a rare and catastrophic treatment-resistant form of childhood epilepsy for which there is currently no cure. It begins in the first year of life in an otherwise healthy infant. Children with Dravet syndrome typically experience poor development of language and motor skills, hyperactivity, and difficulty relating to others.

    Lennox-Gastaut syndrome is a rare and often debilitating form of childhood-onset epilepsy. The syndrome is characterized by a triad of signs including multiple seizure types, moderate to severe cognitive impairment, and an abnormal EEG with slow spike- wave complexes. Lennox-Gastaut syndrome constitutes between 1-4% of pediatric epilepsies and typically appears between the second and sixth year of life.

    Recently, the FDA has granted Fast Track designation to GWPH's investigational cannabidiol product, Epidiolex(NYSE:R), in the treatment of Dravet syndrome.

    FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier.

    According to GWPH, initial data on Epidiolex provides promising signals of efficacy and safety in children with treatment-resistant epilepsy, including patients with Dravet syndrome.

    GWPH recently raised total net proceeds after expenses of approximately $118 million from a U.S. public offering of American Depositary Shares (ADSs) on the NASDAQ Global Market

    GWPH's preparations for Phase 3 clinical trials in both Dravet and Lennox-Gastaut syndromes are advancing rapidly and the company looks forward to the start of the first pivotal placebo-controlled trial in the second half of this year.

    GWPH said that the funds raised in the follow-on offering will not only allow the company to complete these development programs but also to commence pre-launch activities in the United States and build-up of inventory in readiness for future launch

    In parallel with its Epidiolex program, GWPH also said that it is progressing towards the conclusion of its U.S. Phase 3 cancer pain trials for Sativex, the world's first plant-derived cannabinoid prescription drug, and looks forward to reporting initial top-line data from the first trial around the end of 2014. Sativex(R) is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States

    http://static.cdn-seekingalpha.com/uploads/2014/8/21/saupload_gwphch21.png

    GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

    More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/8/21/saupload_gme.jpgGameStop Corp. (NYSE:GME)

    Keep a close eye on GME. The company reported financial results stronger than anticipated.

    For the second quarter 2014, GME posted total global sales of $1.73 billion, a 25.1% increase year over year, net earnings of $24.6 million, a 134.3% increase compared to the same period the prior year, and diluted earnings per share of $0.22, representing a 144.4% increase compared to diluted earnings per share of $0.09 in the second quarter 2013

    According to its business outlook, for the third quarter fiscal 2014, GME expects diluted earnings per share to range from $0.58 to $0.64, while for the full fiscal year 2014, GME expects diluted earnings per share to range from $3.40 to $3.70.

    http://static.cdn-seekingalpha.com/uploads/2014/8/21/saupload_gmech.png

    GME is a global, multichannel video game, consumer electronics and wireless services retailer.

    **

    Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Aug 21 10:51 PM | Link | Comment!
  • Achillion Pharmaceuticals (ACHN) U.S. Patent For HCV NS5A Inhibitor, VisionChina Media (VISN) Excelsus Growth Performance

    http://static.cdn-seekingalpha.com/uploads/2014/8/15/saupload_achn.jpg Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

    In 2011, ACHN discovered and nominated the investigational compound, ACH-3102. ACH-3102 is a structurally distinct second-generation NS5A inhibitor which has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C (HCV).

    The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including more than 5 million people in the United States.

    The U.S. Patent & Trademark Office has granted ACHN U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.

    ACHN recently reported a 100% sustained virologic response rate (SVR4) from an ongoing Phase 2 proxy study evaluating its ACH-3102, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naive genotype 1 chronic hepatitis C virus (HCV) infection.

    Achieving 100% SVR4 with eight weeks of treatment with sofosbuvir serving as a nucleotide proxy indicate that dosing 50 mg once daily of ACH-3102 plus a nucleotide inhibitor has the potential to achieve commercially competitive results for curing HCV in a short duration, ribavirin-free doublet.

    On Monday, brokerage firm Deutsche Bank upgraded ACHN from Hold to Buy and raised its price target on the company from $6.00 to $17.00 per share.

    http://static.cdn-seekingalpha.com/uploads/2014/8/20/saupload_achnch2.png

    ACHN is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease, including HCV and resistant bacterial infections.

    More about Achillion Pharmaceuticals, Inc. (ACHN) at www.achillion.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/8/20/saupload_visn1.jpg VisionChina Media Inc. (NASDAQ:VISN)

    Keep a close eye on VISN. The company reported strong performance on its financial results.

    For the second quarter 2014, VISN posted total revenues of $30.5 million, an increase of 14.2% year over year and 38.3% sequentially, operating profit of $2.0 million versus operating loss of $5.2 million in the same period the prior year and operating loss of $7.1 million in the previous quarter, and non-GAAP net income attributable to VISN shareholders of $2.5 million, compared to non-GAAP net loss of $5.1 million in the second quarter 2013.

    According to its business outlook, VISN estimates its advertising service revenue for the third quarter of 2014 will be between $30.0 million and $31.5 million, representing year-over-year growth of 6.5% to 11.8%.

    http://static.cdn-seekingalpha.com/uploads/2014/8/20/saupload_visnch.png

    VISN operates an out-of-home advertising network on mass transportation systems, including buses and subways.

    More about VisionChina Media Inc. (VISN) at www.visionchina.cn.

    **

    Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Aug 20 4:56 AM | Link | Comment!
  • Monster Beverage Corp (MNST) Coca-Cola Monster Deal, Achillion Pharmaceuticals (ACHN) Promising Results On Hepatitis C Drug Trial

    http://static.cdn-seekingalpha.com/uploads/2014/8/15/saupload_mnst.jpg Monster Beverage Corp. (NASDAQ:MNST)

    Keep a close eye on MNST. The company has entered into definitive agreements with The Coca-Cola Company, that will accelerate MNST's opportunity to grow internationally.

    The partnership strategically aligns both companies for the long-term by combining the strength of The Coca-Cola Company's worldwide bottling system with MNST's dedicated focus and expertise as a leading energy player globally.

    The Coca-Cola Company will make a net cash payment of $2.15 billion in exchange for an approximately 16.7% ownership interest in MNST, and transfer its worldwide energy business - which includes drinks like NOS, Full Throttle, Burn, Mother and Play - to MNST. Meanwhile, MNST will issue to The Coca-Cola Company the shares of MNST common stock, transfer its non-energy business - which includes drinks like Hansen's Natural Sodas, Peace Tea, Hubert's Lemonade and Hansen's Juice Products - to The Coca-Cola Company, and enter into expanded distribution arrangements.

    http://static.cdn-seekingalpha.com/uploads/2014/8/15/saupload_mnstch.png

    MNST is a leading marketer and distributor of energy drinks and alternative beverages

    More about Monster Beverage Corp. (MNST) at www.monsterbevcorp.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2014/8/15/saupload_achn.jpg Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

    The hepatitis C virus (HCV) is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including more than 5 million people in the United States. Chronic hepatitis, if left untreated, can lead to permanent liver damage that can result in the development of liver cancer, liver failure or death.

    ACHN reported a 100% sustained virologic response rate (SVR4) from an ongoing Phase 2 proxy study evaluating its ACH-3102, a second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naive genotype 1 chronic hepatitis C virus (HCV) infection.

    According to ACHN, ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies and the company believes these studies also confirm a differentiated efficacy profile for an NS5A inhibitor.

    Achieving 100% SVR4 with eight weeks of treatment with sofosbuvir serving as a nucleotide proxy indicate that dosing 50 mg once daily of ACH-3102 plus a nucleotide inhibitor has the potential to achieve commercially competitive results for curing HCV in a short duration, ribavirin-free doublet.

    http://static.cdn-seekingalpha.com/uploads/2014/8/15/saupload_achnch.png

    ACHN is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease, including HCV and resistant bacterial infections.

    More about Achillion Pharmaceuticals, Inc. (ACHN) at www.achillion.com

    **

    Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Aug 15 12:43 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.